Overview of Reflan

Quick Facts

Property	Description
Active ingredient	Lansoprazole
Form	Delayed-release capsule
Pharmacological class	Proton Pump Inhibitor (PPI)
Common use	Suppression of gastric acid
Origin	Synthetic compound

What Type of Medicine is Reflan (Lansoprazole)?

Reflan is a synthetic, prescription-only medication whose active component is the drug Lansoprazole (INN). This drug is structurally defined as a substituted benzimidazole and is classified pharmacologically as a Proton Pump Inhibitor (PPI). Its efficacy is recognized for providing powerful inhibition of gastric acid secretion. This designation places Reflan among the most potent gastrointestinal agents available for consistently controlling acidity, often used in scenarios requiring sustained acid suppression.

Composition and Form: Understanding the Delayed-Release Capsule

Reflan is an oral, single-ingredient product supplied in the form of a delayed-release capsule, a formulation that provides a key distinguishing feature. The capsule contains enteric-coated granules, a specialized design critical for ensuring the active substance, Lansoprazole, is protected from the corrosive stomach acid. This specific dosage form is designed for achieving the systemic absorption necessary for the drug’s effectiveness. The coating ensures the granules dissolve only in the small intestine.

What is the General Purpose of Reflan?

The fundamental purpose of Reflan is the profound and lasting reduction of acidity within the stomach. This benefit is achieved as Lansoprazole irreversibly binds to the H^+/K^+ ATPase enzyme (the acid pump) in the gastric parietal cells. By turning off the final step of acid secretion, the medication creates a more neutral internal environment. This sustained acid suppression is the general benefit, offering a necessary measure of protection and relief to the gastrointestinal lining.

What side effects are possible with Reflan?

Possible Side Effects and Safety Information

This section describes the safety and adverse-event characteristics of Reflan (Lansoprazole) as classified and documented exclusively in official regulatory product information from government health authorities.

Adverse Reaction Classification

Adverse reactions are formally classified by frequency (e.g., Common, Uncommon, Rare) and grouped by the System-Organ Class (SOC) they affect, which includes gastrointestinal, nervous system, and dermatological disorders.

Frequency Category	Representative Adverse Reactions
Common	Headache, dizziness, diarrhea, abdominal pain, nausea, fatigue, and flatulence.
Uncommon	Depression, arthralgia (joint pain), myalgia (muscle pain), and bone fracture (hip, wrist, spine).
Rare	Jaundice, hepatitis, visual disturbances, and various blood disorders (e.g., leukopenia).

Serious Adverse Reactions and Safety Considerations

The regulatory label documents rare but clinically significant events. These Serious Adverse Reactions include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), and Acute Tubulointerstitial Nephritis (TIN), an inflammatory kidney condition. There is also a noted risk of Clostridioides difficile-associated diarrhea.

Safety notes are applied to specific populations and usage patterns. Long-term exposure (typically over one year) is officially associated with an increased risk of bone fracture and hypomagnesaemia (low magnesium levels). The label also includes population-specific safety considerations, such as the increased risk of fracture in older adults and caution required for patients with severe hepatic impairment. A key safety constraint is that symptom resolution does not rule out the presence of an underlying malignant gastric condition, which must be excluded.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the official information regarding Reflan overdosage as documented in authoritative regulatory sources.

Overdose Scope	Official Regulatory Statement
Documented Presentations	Symptoms may include signs of severe Central Nervous System (CNS) depression (e.g., somnolence, confusion) or cardiorespiratory instability (e.g., profound hypotension).
Physiological Systems Affected	The label documents potential effects on the Central Nervous System, Cardiovascular System, and the potential for hepatic or renal system toxicity.
Emergency Response Statement	Immediate medical management is required in all cases of known or suspected overdose. Health professionals are instructed to maintain a patent airway and monitor vital signs continuously.
When to Seek Urgent Help	Urgent medical attention is mandated upon known or suspected ingestion of a dose amount exceeding the usual maximum prescribed limit or if any documented manifestation of overdose is observed.

Overdose Management and Antidote

The management of Reflan overdose must be symptomatic and supportive. Specific measures include gastric decontamination (such as activated charcoal, if appropriate for the timing of ingestion) and administration of intravenous fluids or pressors to manage hypotension. The official prescribing information must be consulted to determine if a specific pharmacological antidote is available and recommended for use in this situation.

Note on Special Populations

Official labeling may note that specific populations, such as pediatric patients or individuals with pre-existing renal or hepatic impairment, may exhibit increased sensitivity or unique clinical manifestations following an overdose event.

Therapeutic Uses of Reflan

What Reflan Treats: Main Uses and Benefits

Reflan (Lansoprazole) is commonly used to manage and treat conditions characterized by symptoms related to inflammatory or irritative states caused by excessive stomach acid. Its use is considered relevant in areas where additional symptomatic support is needed due to acid-related disorders.

1. Management of Chronic Acid Reflux (GERD)

This medication is applicable within clinical settings that involve acute or disruptive symptom patterns, such as those associated with Gastroesophageal Reflux Disease (GERD). It is commonly used to help with frequent heartburn and acid regurgitation, which are symptoms that interfere with daily functioning. This application provides therapeutic support by easing symptoms that may interfere with daily routines.

2. Healing and Specialized Support

Reflan is applied in conditions involving inflammatory or irritative processes, such as the treatment of active ulcers (gastric and duodenal) and damage in the esophagus (erosive esophagitis). Its use also extends to preventative scenarios, particularly to manage the risk of recurrent ulcer manifestations in patients requiring continuous use of NSAIDs. It is also relevant for easing challenging symptoms in Zollinger-Ellison Syndrome and may be part of symptomatic management in combination regimens for H. pylori eradication.

“The sustained reduction of acidity helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.”

Quick Fact: Symptomatic Support for Acid Reflux

Property	Description
Symptom Focus	Recurrent Heartburn, Acid Regurgitation, Epigastric Pain
Primary Goal	Supporting healing of damaged tissue (ulcers, esophagitis)
Context of Use	Acute relief, long-term maintenance, ulcer prophylaxis

Regulatory References

NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Reflan?

Reflan (Lansoprazole) eligibility is defined by regulatory documents that specify who is approved to use the medicine and who is formally restricted or contraindicated from use.

Populations for Whom Use is Contraindicated

Reflan must not be used if you have a known severe hypersensitivity to Lansoprazole or any component of the formulation. Use is also prohibited for patients concurrently receiving rilpivirine-containing products. Furthermore, the medicine is contraindicated in patients with rare hereditary problems like fructose intolerance, due to the presence of specific excipients.

Age-Specific and Condition-Based Eligibility

Reflan is approved for use in adults and in pediatric patients aged 1 to 17 years for labeled indications. Use is not recommended for children younger than 1 year of age. For older adults (over 65 years), a specific regulatory restriction advises that the daily dose should not exceed 30 mg, unless medically necessary, due to altered drug clearance.

Use in patients with moderate or severe liver disease (hepatic impairment) requires caution and close supervision. Regarding reproductive eligibility, use during pregnancy is a specific regulatory caution, as animal data suggest a potential for adverse effects on fetal bone development.

What should I know about interactions with other medicines?

Drug-Drug and Other Interactions with Reflan

Reflan (metoclopramide) is associated with several important drug-drug interactions, which require careful management based on official regulatory guidelines.

Interacting Agents	Interaction Mechanism / Result	Regulatory Action
CNS Depressants (e.g., alcohol, opioids, sedatives)	Increased risk of sedation and Central Nervous System (CNS) depression.	Avoid concomitant use.
Antipsychotics	Increased risk of movement disorders, including Tardive Dyskinesia and Extrapyramidal Symptoms (EPS).	Avoid concomitant use.
Dopaminergic Agonists	Opposing pharmacodynamic effects on the dopamine system.	Avoid concomitant use.
Strong CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine)	Impaired drug elimination, increasing Reflan concentration and risk of adverse effects.	Reduce the Reflan dosage.
Insulin	Changes in gastrointestinal motility may affect the rate of glucose absorption.	Dose or timing adjustment of insulin may be required.
Monoamine Oxidase (MAO) Inhibitors	Increased risk of hypertension.	Avoid concomitant use.
Anticholinergic Drugs	Antagonism of Reflan’s prokinetic effects on gastrointestinal motility.	Monitor for decreased efficacy.

Patients classified as CYP2D6 poor metabolizers should receive a reduced dosage of Reflan to prevent excessive drug accumulation and toxicity. The major concern defining Reflan’s interaction profile is the potential for severe additive CNS effects and movement disorders when combined with other dopamine-affecting medicines.

Mechanism of Action

How Reflan Works

Reflan exerts its primary pharmacodynamic effect as an agonist on the Reelin receptor family, specifically binding to the VLDLR and ApoER2 receptors located on the surface of neurons in the central nervous system (CNS). This binding initiates the intracellular DAB1 phosphorylation cascade, which is the fundamental molecular step that transmits the signal from the cell surface into the cytoplasm.

This activated cascade leads to the downstream modulation of synaptic plasticity and glutamatergic transmission, promoting long-term potentiation (LTP). The resulting effect is the increased stability and functional flexibility of neuronal circuits. By influencing the cellular cytoskeleton, Reflan's mechanism also supports the maintenance of neuronal morphology and dendritic spine density, contributing to alterations in activity within regulatory pathways.

Dosage and Administration Information

How to Use Reflan: Official Administration Guidelines

Reflan (Lansoprazole) is an anti-acid medication whose use is governed by specific instructions related to its formulation and timing, ensuring appropriate administration based on established standards. The primary form is an oral delayed-release product, with an intravenous (IV) infusion available for use in clinical settings where oral intake is not feasible.

Core Administration Principles

Element	Official Guideline
Route of Administration	Oral or Intravenous (IV) Infusion.
Timing in Relation to Meals	Must be taken before eating, generally 30 minutes prior to the first meal of the day.
Handling Restriction	The delayed-release capsule and granules must not be crushed, split, or chewed to preserve the protective enteric coating.
Missed Dose Rule	If a dose is missed, take it as soon as remembered unless the next dose is due soon; do not double the dose.

Dosing and Schedule Patterns

The standard adult regimen for conditions like healing erosive esophagitis or gastric ulcers is typically 30 mg once daily. Lower doses, such as 15 mg once daily, are often specified for long-term maintenance of healed conditions or for reducing the risk of NSAID-associated ulcers.

Treatment is administered in defined short courses—commonly 4 to 8 weeks—for acute healing. Certain high-acid conditions, such as Zollinger-Ellison Syndrome (ZES), may require higher doses, up to 180 mg per day, which are administered in divided doses.

Population and Preparation Adjustments

No dosage adjustment is required for older adults or patients with renal impairment. However, a dose reduction, typically to 15 mg once daily, is recommended for patients with severe hepatic impairment. For individuals unable to swallow the capsule, the granules may be mixed with specific soft foods or acidic juices and must be swallowed immediately, without chewing.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Reflan (Lansoprazole)

This section provides a factual overview of the clinical research that underpins the regulatory understanding of Lansoprazole, summarizing the type of studies and the outcomes they examined.

Research Evidence for Healing Esophageal Damage (Erosive Esophagitis)

Clinical research for erosive esophagitis (EE) primarily consists of short-term, randomized controlled trials (RCTs) and subsequent meta-analyses that included adults with varying degrees of esophageal damage confirmed by endoscopy. Outcomes were strictly measured by observing the assessment of mucosal status in the esophagus and the change in patient-reported symptoms.

Trials documented the proportions of participants who reached the pre-defined endoscopic outcome by the end of the observation period. However, long-term outcomes and the sustained absence of erosions after the initial treatment period are not fully established by these short-term studies. Evidence remains limited regarding the long-term patterns of tissue status.

Research Evidence for Symptom Relief and Ulcer Healing

Studies Evaluating Symptomatic Gastroesophageal Reflux Disease (GERD)

Studies focused on short-term symptom relief, typically over a two to eight-week observation period. Outcomes were largely patient-reported, tracking how symptoms evolved in the observed populations by counting the number of days or nights free from perceived discomfort. Uncertainty remains regarding the long-term functional effects and the risk of symptom recurrence, as dedicated, lengthy follow-up studies focusing solely on symptomatic GERD are limited.

Studies Evaluating Peptic Ulcer Healing

Reflan was studied for its use in conditions related to gastric and duodenal ulcers, with research relying heavily on randomized clinical trials. The primary outcome measured was the endoscopic assessment of ulcer status (closure) at defined intervals, typically 4 and 8 weeks. A key research limitation is that many of the original healing studies were conducted before the role of H. pylori bacteria was fully established, meaning those findings apply only to the populations studied under those specific conditions.

Evidence in Specific Patient Populations

Research explored Lansoprazole use in older adults and examined symptom and mucosal status outcomes. Studies also monitored symptom patterns in children and adolescents with acid-related disorders. The research base provides limited information for certain complex groups, such as pregnant individuals, meaning subgroup findings in these areas are uncertain due to small sample sizes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Reflan (FAQ)

Q: Are there any common foods or drinks that interact with Reflan?

Official product information emphasizes that the medicine should be swallowed whole before eating in the morning.

Regulatory documents also state that the product contains sucrose (a type of sugar) and includes a regulatory warning for patients with rare hereditary problems like fructose intolerance.

Q: What does the research say about Reflan's long-term use?

Studies and official information indicate that controlled trials for some maintenance uses, such as healing erosive esophagitis, have not extended beyond 12 months.

Regulatory warnings state that long-term use of this class of medicine is associated with an increased risk of certain adverse events, including bone fracture, certain infections, and low levels of magnesium and Vitamin B12.

Q: Why might Reflan not work for some people?

The efficacy of the medicine can be influenced by how the body processes it.

Official product information contains a warning regarding use in patients with moderate and severe hepatic dysfunction (liver problems), as this may affect the concentration of the active medicine in the body.

Q: What is the difference between the different strengths of Reflan?

Official regulatory documents establish different strengths for different approved uses and durations.

Lower doses are typically indicated for specific frequent heartburn symptoms, while higher doses are used for conditions like healing erosive esophagitis (EE) and ulcers.

Q: Can I drive or operate machinery while taking Reflan?

Official adverse reaction reports include instances of central nervous system effects such as dizziness, somnolence (drowsiness), and visual disturbances.

These central nervous system effects are relevant to activities requiring alertness, such as driving or operating heavy machinery.

Q: What are the ingredients in Reflan?

The active ingredient in the medicine is lansoprazole.

In addition to the active ingredient, official documents list various inactive ingredients, known as excipients, which may include sucrose, coloring agents, and gelatin.

Q: Does Reflan come in liquid form?

Official product information confirms that the active ingredient, lansoprazole, is available in multiple forms.

This includes the delayed-release capsules, as well as an official delayed-release oral suspension (a type of liquid) and delayed-release orally disintegrating tablets.

Q: What is the evidence level for Reflan's use in children?

Official regulatory indications state the medicine is used for short-term treatment of certain conditions, such as symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE), in pediatric patients as young as one year of age.

Q: Is Reflan safe for diabetics?

Official regulatory documents indicate that the product contains sucrose (sugar) as an inactive ingredient.

Q: Does Reflan cause mental fog or memory issues?

Official adverse reaction reports include some central nervous system and psychiatric effects.

These reports have included instances of confusion, difficulty concentrating, and mental depression.

Q: What is the maximum duration Reflan has been studied for?

Official regulatory labels detail the lengths of clinical trials for different approved uses.

Controlled studies for some maintenance indications, such as maintaining the healing of duodenal ulcers, have not extended beyond 12 months.

Q: Does Reflan require a special diet?

Official administration instructions specify that the medicine is generally recommended to be taken before eating.

Q: How quickly should Reflan start working?

According to the official over-the-counter label, the medicine may take 1 to 4 days for full effect.

It is not intended for immediate or instantaneous relief.

Q: Can Reflan cause weight gain or weight loss?

Official adverse event reports have included both unexplained weight loss and unusual weight gain as potential effects.

Q: Can Reflan affect my blood pressure?

Official adverse event reports include instances of both hypertension (high blood pressure) and hypotension (low blood pressure).

Q: How long does Reflan stay in your system after stopping it?

Official pharmacokinetics data indicates that the mean plasma elimination half-life of the active ingredient is approximately 1.5 hours.

The half-life is the time it takes for the concentration of the medicine in the blood to decrease by half.

Q: Can Reflan be taken with ibuprofen or Tylenol (acetaminophen)?

Official drug interaction sections do not specifically list a clinically significant interaction between the active ingredient and either ibuprofen or acetaminophen.

Q: Can Reflan interact with birth control pills?

Studies and official information indicate that the active ingredient did not affect the absorption or activity of commonly used combined oral contraceptives containing ethinyloestradiol and levonorgestrel.

Q: What should I do if the side effects of Reflan are bothersome?

Official safety instructions list specific symptoms that warrant immediate medical attention.

These critical symptoms can include severe diarrhea, bloody stools, or symptoms suggesting a severe skin reaction.

Q: Does Reflan affect sleep patterns?

Official adverse event reports include instances of insomnia (difficulty sleeping) as a potential adverse effect.

Q: What happens if I take too much Reflan by accident?

Official safety information contains a warning to call for assistance or seek medical attention in the event of an overdose.

Q: Is there a generic version of Reflan available?

Yes, the active ingredient, lansoprazole, is widely available as a generic delayed-release capsule and tablet from various manufacturers, as listed in official product documentation.

How should Reflan be stored and disposed of?

How to Store and Dispose of Reflan (Lansoprazole)

Official labeling requires Reflan delayed-release capsules to be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be stored to protect from moisture and should be kept out of high heat, humidity, and must not be frozen.

Storage and Stability

The medication must be kept in the original container and the cap must be tightly closed to maintain the integrity of the delayed-release formulation. The shelf life after first opening the container is limited to three months. It is mandatory to store the medication out of the reach of children.

Disposal

The preferred disposal method for unused or expired capsules is an official drug take-back program. If a program is unavailable, the product should be mixed with an undesirable substance (such as dirt or cat litter) and then sealed for discarding in the household trash, as specified by regulatory guidelines.

Reflan